GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership of its guru Hal Barron. After taking over in 2017 Walmsley is looking for a ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK chief scientific officer Tony Wood stated: “Collaboration is at the heart of scientific progress and is fundamental to ...

GSK is delivering consistent financial performance. Looking to the end of this year and beyond, we're even more confident that the progress we're making in portfolio development and in R&D support ...

The upgraded manufacturing campus will be equipped to crank out commercial drugs and vaccines plus house an R&D pilot plant to manufacture medicines for clinical trials. GSK plans to add about 200 ...